Drug Discovery World

NOVEMBER 16, 2022

2 Phase I/II trial of TAC01-HER2 in patients with human epidermal growth factor receptor 2 (HER2) positive solid tumours. . TAC01-HER2 is a novel cell therapy that consists of genetically engineered autologous T cells expressing T-cell Antigen Coupler (TAC) that recognises HER2. .

Genetic Engineering 52

Genetic Engineering Engineer Genetics Trials 52

Drug Discovery World

FEBRUARY 3, 2023

No treatment or vaccine for SUDV disease is licensed, although candidates are in clinical and preclinical trials. One of these candidates is VSV-SUDV, developed and tested by scientists at NIH’s National Institute of Allergy and Infectious Diseases in Hamilton, Montana.

Vaccination 52

Vaccination Vaccine Genetic Engineering Protein 52

pharmaphorum

FEBRUARY 18, 2021

Researchers from the University of Texas Medical Branch based their findings on lab tests using SARS-CoV-2 coronaviruses that were genetically engineered to have the same mutations as those in the strain that is causing scientists so much concern.

Immune Response 52

Immune Response Genetic Engineering Vaccination Vaccine 52

Pharmaceutical Technology

APRIL 5, 2023

And my estimate is that between 25,000 and 30,000 patients have been treated with those therapies globally, which does not include patients treated in clinical trials. We have the emergence of this new pillar of medicine, which is out of the lab and beyond clinical trials now. But there is that significant challenge.

Gene Therapy 147

Gene Therapy Gene Engineer Production 147

WCG Clinical

MAY 28, 2024

CAR-T Cells Target Harmful B Cells in Lupus CAR-T cell technology, which uses genetic engineering to direct white blood cells to attack specific molecular targets, was originally proposed for treatment of HIV infection and hematological malignancies. WCG has many ways to support cell and gene therapy clinical trials for lupus.

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials FDA Approval 52

XTalks

MARCH 28, 2024

Early clinical trials have shown promising results and this therapy could become a valuable addition towards CRC treatment in the future. Gene Editing and CAR T-Cell Therapy Genetic engineering technologies, such as CRISPR-Cas9, are providing newer potential avenues for cancer treatment.

Gene Editing 59

Gene Editing Life Science Clinical Trials Clinical Trials 59

Bioengineer

JULY 21, 2021

Parker, PhD, Editor-in-Chief of Stem Cells and Development and The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI. ###. (New Orleans, USA) represents a truly international effort to advance the robust and accurate assessment of wound healing,” states Graham C. About the Journal.

Genetic Engineering 52

Genetic Engineering Development Engineer Genetics 52

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration, European Medicines Agency and/or Medicines and Healthcare products Regulatory Authority in the United Kingdom. NVX-CoV2373 is a protein-based vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease. About NVX-CoV2373. and Australia.

Protein 52

Protein Vaccination Vaccine Immune Response 52

Cloudbyz

MARCH 5, 2024

In the intricate dance of drug discovery and development, two protagonists emerge as the cornerstones of modern medicine: biologics and small molecules. Monitoring and managing immunogenicity is a complex aspect of clinical trials for biologics.

Development 81

Development Drugs Manufacturing Immune Response 81

The Pharma Data

APRIL 27, 2023

It is also an off-the-shelf therapy, meaning that people do not have to wait for cell collection and genetic engineering before starting treatment, which could be particularly important for patients who are at a high-risk of their disease progressing. A final decision is expected from the European Commission (EC) in the near future.

Genetic Engineering 40

Genetic Engineering Clinical Development Antibody Medicine 40

Bioengineer

JULY 15, 2021

Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. Mary Ann Liebert, Inc., publishers (https:/ / www. liebertpub. com/ ) website.

Nurses 52

Nurses Genetic Engineering Engineer Genetics 52

The Pharma Data

OCTOBER 27, 2020

He is also a principal investigator and a translational chair on several institutional and cooperative group clinical trials exploring novel immunotherapy combinations in gynecologic cancers and other solid tumors. He has led several investigator-initiated trials from phase 1 through phase III. Dean A.

Antibody 52

Antibody Genetic Engineering Engineer Development 52

Drug Discovery World

MARCH 13, 2023

Between the 24 therapies already approved by the FDA 1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. Genetic Engineering & Biotechnology News. The cell and gene therapy (CGT) landscape has grown significantly in the past year. August 2020. April 4, 2022.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

Drug Discovery World

JULY 5, 2023

For example, in CAR-T-cell therapy, scientists can take T-cells from a patient and ex vivo (outside the body) genetically engineer them to effectively target and kill cancerous cells, then infuse them back in to the patient.

Research 98

Research Protein Scientist Immune Response 98

The Pharma Data

JULY 27, 2021

Amgen’s R&D resources and its extensive clinical experience in immuno-oncology are ideally suited to applying and advancing Teneobio’s differentiated technologies and multispecific antibodies to deliver transformative medicines,” said Roland Buelow, Ph.D., chief executive officer of Teneobio.

Production 52

Production Antibody Sales Manufacturing 52

Drug Discovery World

FEBRUARY 15, 2023

Over 250 clinical trials are currently in progress, and novel immuno-oncological treatments are already proving to be successful. Genetically engineered mouse models (GEMM) recapitulate the stromal biology of different human cancers including the tumour microenvironment that regulates the disease process. doi:10.15252/emmm.201606857pmid:[link]

Research 52

Research In-Vitro In-Vivo Development 52

Drug Discovery World

JANUARY 23, 2023

Increasing interest in CRISPR-Cas gene editing systems over recent years has delivered innovative developments in precision genome engineering technologies, holding enormous potential for applications across the healthcare sector. The first in-person iPSC-derived regenerative therapy trial took place at Kyoto University, Japan.

Gene Editing 52

Gene Editing Gene Engineer DNA 52

The Pharma Data

SEPTEMBER 8, 2020

More specifically, the agency requires that scientific evidence for regulatory approval must come from large, high quality clinical trials that are randomized and observer-blinded, with an expectation of appropriately designed studies with significant numbers of participants across diverse populations.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Drug Discovery World

JULY 22, 2022

For example, in randomised clinical trials of patients with non-small cell lung cancer (NSCLC), pembrolizumab has been shown to be effective in slowing down disease progression and improving survival rates 1. Clinical trials show feasibility in studying and treating solid tumours.

In-Vivo 52

In-Vivo Engineer In-Vitro Antibody 52

The Pharma Data

SEPTEMBER 8, 2020

More specifically, the agency requires that scientific evidence for regulatory approval must come from large, high quality clinical trials that are randomized and observer-blinded, with an expectation of appropriately designed studies with significant numbers of participants across diverse populations. Cambridge, UK. Johnson & Johnson.

Vaccination 52

Vaccination Vaccine Containment Clinical Trials 52

Drug Discovery World

NOVEMBER 17, 2022

The rapidly growing area of synthetic biology – including molecular biology, biotechnology, biophysics, and genetic engineering – is having a marked impact on the drug discovery landscape. Cilagicin is still far from human trials. Now researchers will need to focus on increasing its biological and technological relevance.

Bacteria 52

Bacteria Engineer Gene Genetics 52

pharmaphorum

JANUARY 10, 2022

The opt-in has been prompted by the results of a phase 2 trial of ensovibep (MPO420), which showed that a single intravenous dose of the drug was able to not only reduce viral load in non-hospitalised COVID-19 patients over eight days, but also cut the risk of hospitalisation or death by 78% versus placebo.

Trials 52

Trials Drugs Antibody Genetic Engineering 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Innovation S-curve for the pharmaceutical industry Gene splicing using nucleases is a key innovation area in the pharmaceutical industry Nucleases play a fundamental role in the field of recombinant DNA technology, or genetic engineering. Nucleases are enzymes that hydrolytically cleave the phosphodiester backbone of DNA.

Gene Splicing 130

Gene Splicing Gene Recombinant DNA Technology DNA 130

Drug Discovery World

MAY 10, 2023

This stage is more highly regulated and consists of both preclinical testing and clinical trials. Toxicologic Pathology. 2011;39(4):716-744. She has an AB in chemistry from Princeton University and PhD in chemistry from the Pennsylvania State University.

Bioassay 52

Bioassay Genotoxicity Drugs In-Vivo 52

XTalks

AUGUST 17, 2020

With several biologics in the pipeline, including one in early stage clinical trials for head and neck cancer, the company is positioned to engineer highly specific biologics against immune targets in the body. Suri, as the company’s approach is “a very unique marriage between very rational protein engineering and immunology.”.

Protein 98

Protein Engineer Immune Response In-Vivo 98

pharmaphorum

SEPTEMBER 13, 2022

Although early accounts of an illness akin to leukaemia can be traced back to Ancient Greece, the first official description of blood cancer didn’t appear until 1832, when British pathologist and pioneer of preventative medicine Thomas Hodgkin used the controversial concept of micrology to identify the abnormalities in the lymphatic system.

Genome Project 98

Genome Project Genome Genomics DNA 98

Pharmaceutical Technology

JUNE 16, 2023

Clinical-stage cell therapy company Tessa Therapeutics have announced positive safety and efficacy data from the trial (NCT04288726 of TT11X, its off-the-shelf CD30.CAR-modified In tandem with Baylor College of Medicine, Tessa enrolled 18 patients with R/R Hodgkin’s Lymphoma in the trial, all of whom had been heavily pre-treated.

Genetic Engineering 130

Genetic Engineering Genetics Trials Engineer 130